BMJ (Clinical research ed.)

Hair loss risk linked to diabetes drugs called GLP-1 receptor agonists in adults with type 2 diabetes

Updated

Abstract

An examination of glucagon-like peptide-1 (GLP-1) receptor agonists may reveal an association with the risk of hair loss in adults with type 2 diabetes.

  • GLP-1 receptor agonists are being compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors.
  • The focus is on adults with type 2 diabetes and their risk of developing alopecia.
  • The study aims to clarify the potential link between these medications and hair loss.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: support from the National Institutes of Health for the submitted work; DAA has received consulting fees from VAL Health, Thrive Global, and SelectDr, as well as payment from Deloitte, outside the submitted work; YL has received grants or contracts from the National Heart, Lung, and Blood Institute, the Patient-Centred Outcomes Research Institute, Sentara Research Foundation, and Novartis, outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free